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Open Forum Infectious Diseases
MAJOR ARTICLE

Optimizing Hepatitis C Virus (HCV) Treatment in a US
Colocated HCV/Opioid Agonist Therapy Program
Jackie Habchi,1 Aurielle M. Thomas,2 Sophie Sprecht-Walsh,1 Elenita Arias,1 Jeffrey Bratberg,2 Linda Hurley,1 Susan Hart,1 and Lynn E. Taylor3,
1
CODAC Behavioral Healthcare, Providence, Rhode Island, USA, 2University of Rhode Island, Providence, Rhode Island, USA, and 3CODAC Behavioral Healthcare and University of Rhode Island,
Providence, Rhode Island, USA

To achieve hepatitis C virus infection (HCV) elimination, a
greater proportion of people who inject drugs (PWID) living
with HCV need to be diagnosed, treated, and cured. PWID
constitute the largest group of persons in the United States infected with HCV and account for most new infections [1].
PWID may be successfully treated with direct-acting antiviral
(DAA) agents. Contemporary meta-analyses demonstrate high
sustained virologic response (SVR) rates among PWID with or
without opioid agonist therapy (OAT; methadone [μ-receptor full
agonist] and buprenorphine [μ-receptor partial agonist]) [2, 3].
While national and international guidelines support HCV treatment scale-up for PWID, in the United States, a minority receive
treatment.
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Historically, HCV care has been delivered in specialist settings. Embedding HCV treatment into services utilized by
PWID can facilitate access, as drug-involved populations may
face stigma and difficulty navigating traditional health care environments. The advent of DAAs simplifies HCV therapy and
enables prescription by a broad range of providers. Delivering
all elements of care under 1 roof may be accomplished with
colocated HCV and addiction care.
More than four out of five PWID predominantly inject opioids, making HCV treatment integration at OAT programs
essential [4]. OAT, the key treatment for opioid use disorder
(OUD), reduces illicit opioid use, withdrawal symptoms, and
opioid-related morbidity and mortality [5]. OAT facilitates
HCV screening, treatment initiation and SVR, and reduces incidence and reinfection [4, 6–8]. Administering DAAs in conjunction with OAT and high-coverage needle syringe programs
(NSPs) establishes the optimal preventive strategy [5, 9–11].
Rhode Island (RI), ranked 10th in the nation for overdose
deaths, reported 26 000 individuals with OUD in 2016 [12, 13].
A 2014 study conducted before considering the opioid crisis estimated 16 768 HCV-infected Rhode Islanders [14]. The work
presented was developed given concerns that referral to off-site
subspecialty care was failing a vulnerable population.
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Background. A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated
HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few realworld examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era.
Methods. We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates
during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island’s only nonprofit methadone maintenance program.
Results. Of 275 who initiated DAAs, the mean age (range) was 43 (22–71) years, 34.5% were female, 57.5% had genotype 1a,
23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232/273), while modified intent-to-treat SVR was 93.2%
(232/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty
reinfections were identified over 375.5 person-years of follow-up (rate, 7.99/100 person-years). The median time to first reinfection (interquartile range) was 128 (85.25–202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid
DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps,
differing across 11 RI insurers, taking 45–120 minutes per patient.
Conclusions. DAA treatment was effective among a marginalized population in an urban colocated OAT/HCV program.
Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in
the United States.
Keywords. colocated care; direct-acting antivirals (DAAs); hepatitis C virus infection (HCV); opioid agonist therapy (OAT);
people who inject drugs (PWID).

METHODS
Study Design

Colocated Care Model

CODAC Providence’s HCV Clinic started on May 1, 2014, with
a part-time addiction, HIV, and viral hepatitis–trained internal
medicine physician, an addiction and viral hepatitis–trained
nurse, and a phlebotomist. CODAC Providence uses SMART
Software for methadone dispensing, with paper charts for HCV
care. For the first 4 years, CODAC Providence offered HCV antibody testing; with a reactive result, blood was drawn for HCV
RNA. On May 1, 2018, CODAC Providence began universal,
opt-out, serum HCV antibody screening with reflexive RNA and
genotype upon entry into OAT care, with annual rescreening
for HCV-uninfected patients (Figure 1). Phlebotomy also included testing for HIV, hepatitis A virus (HAV), and hepatitis B
virus (HBV) serologies, liver panel, complete blood count, creatinine, prothrombin time/international normalized ratio, and
rapid plasma reagin plus urine gonorrhea and chlamydia.
Simplified co-located test to treat OAT/HCV pathway
Enter care at OAT clinic:
• Universal (opt-out) HCV Ab screening with reflex
RNA and genotype
• HAV, HBV, HIV serologies
• Liver panel
• CBC, Cr, PT/INR, RPR, urine GC/ chlamydia
Nurse navigates patient to initial HCV physician vist
1st vist: HCV physician evaluation, DAAs ordered
prior authorization (PA) submitted
2nd vist: HCV treatment initiation
SVR
Figure 1.

Simplified colocated test to treat OAT/HCV pathway.
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We conducted a retrospective chart review of all patients treated
on-site for HCV from November 1, 2014, to October 31, 2019, at
CODAC Behavioral Health Inc. (CODAC), RI’s only nonprofit
methadone maintenance program (MMP). CODAC runs 9 geographically dispersed sites providing OAT to >2500 patients.
The largest, in Providence, serves 1000 patients daily, a disenfranchised population with high rates of homelessness, poverty, and frequent incarceration. Included in this review were
patients (1) on OAT at 1 of CODAC’s 8 community sites (the
ninth, a prison/jail, was excluded because patients receive HCV
care in corrections) and (2) attending at least 1 HCV visit at
CODAC Providence. Patients were not financially compensated
for care, nor were they contacted for data collection purposes.
The University of RI’s Institutional Review Board approved this
research.

The nurse navigates HCV-infected patients to an on-site
HCV physician visit, provides viral hepatitis and harm reduction (HR) education, refers to NSP, supplies naloxone, and
coordinates clinic flow. The initial physician visit includes a
full medical history and physical exam, as many patients do
not have primary care providers, along with viral hepatitis,
HIV, polysubstance use, and prevention counseling. If history,
physical exam, aspartate transaminase (AST)-to-platelet ratio
index (APRI) and Fibrosis-4 (FIB-4) yield discordant results,
Fibrosure (LabCorp, Research Triangle Park, NorthCarolina) is
ordered. DAAs are prescribed at visit completion (unless selection is influenced by Fibrosure result). The physician provides
care for HIV, HBV, other sexually transmitted infections, and
cirrhosis, prescribes HIV pre-exposure prophylaxis (PrEP),
and addresses urgent medical concerns. She attempts to link
patients with primary care given that CODAC is not an ambulatory care center but a federally licensed MMP, organizationally and physically separate from mainstream health care [15].
For women of childbearing potential, the physician provides
preconception counseling, recommends planned pregnancies
and avoidance during DAA therapy, and assists with contraception. Patients with cirrhosis are referred to off-site ultrasound
for hepatocellular carcinoma (HCC) and esophageal variceal
surveillance (albeit few make these appointments) with on-site
serum alpha-fetoprotein biannually. On-site HAV and HBV
vaccination began in December 2018.
Patients are accommodated through scheduled and walk-in
visits and may remain in care no matter the number of late or
missed visits. HCV treatment is universal, except for those with
a short life expectancy unable to be remediated by DAAs. For
patients without stable housing, DAA pharmacy deliveries are
accepted and stored on-site. With their approval, patients are
put “on hold” at the methadone window; a nurse sees a SMART
alert to “hold” the dose until conferring with the HCV nurse.
The nurse then reminds the patient of an HCV-related appointment and/or phlebotomy. Patients are encouraged to bring in
injecting partners for simultaneous treatment. Deliveries of
DAAs are provided for patients who are hospitalized or incarcerated midtreatment.
In July 2018, a pharmacist joined the team to lead the DAA
Prior Authorization (PA) process. Prescribing DAAs requires
completing and faxing a PA form, plus supporting laboratory
results, to each patient’s insurer. There are 11 distinct RI insurers, each with different PA requirements and a unique PA
form. The documentation and approval process takes 45 to
120 minutes per patient. PAs require repeat blood tests—HCV
RNA and genotype within 90 days even for patients with documented viremia for years and recent genotyping, prescribed
pan-genotypic regimens—and myriad administrative elements
(phone calls, peer-to-peer discourse, responding to denials).
Each payer dictates a preferred pharmacy, some mail order only,
and a preferred DAA formulary. The pharmacist also obtains

Medicaid DAA Restrictions

Until July 1, 2018, RI Medicaid restricted DAAs to patients
with Meta-Analysis of Histologic Data in Viral Hepatitis
(METAVIR) fibrosis stage F3 or F4; either no drug/alcohol use
for 6 months or current addiction treatment; specialist physician to prescribe DAAs; and, if HIV-infected, confirmation of
antiretroviral therapy or HIV RNA suppression [16]. On July 1,
2018, RI’s DAA Medicaid Restrictions were lifted under threat
of lawsuit [17].
Variables

We conducted a chart review to obtain baseline characteristics for treated patients (age, gender, payer), clinical measures
(HCV genotype, HIV coinfection, HBV coinfection, cirrhosis,
HCC), SVR, and reinfection. We included treatment initiation
and reinfection data from November 1, 2014 (the first date we
could access DAAs) through October 31, 2019, and SVR data
through February 29, 2020. A patient is characterized as having
cirrhosis if they fulfill any of the following: (1) liver biopsy with
METAVIR stage 4 fibrosis; (2) presence or history of any of
the following: ascites, spontaneous bacterial peritonitis (SBP),
esophageal varices, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome; (3) presence of 2 or more
of the following: (a) Fibrosure >0.75, (b) FIB-4 >3.25, (c) APRI
>2, (d) platelets <140 000/mL, (e) transient elastography >12.5
kPa, (f) imaging revealing signs of portal hypertension (spleen

size >13 cm, portal flow mean velocity <12 cm/sec, portal vein
mean diameter >13 mm). Decompensated cirrhosis was defined
as presence or history of ascites, SBP, esophageal varices, hepatic
encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or HCC.
The primary outcome, SVR, was defined as undetectable
HCV RNA 12 weeks post-EOT or at the first follow-up time
point beyond the SVR date for patients missing this blood
draw. SVR was marked as missing when SVR could not be confirmed 12 weeks post-EOT or in subsequent follow-up. HCV
reinfection was defined as the presence of detectable HCV
RNA following undetectable HCV RNA 12 weeks after EOT or
genotype switch.
Ninety-four patients were treated through a research study
providing sofosbuvir/velpatasvir (SOF/VEL). Other patients were prescribed SOF/VEL or a combination of the following medications consistent with society guidelines [18]
and those accessible through each payer at the time of initial
HCV encounter: simeprevir, sofosbuvir, daclatasvir, sofosbuvir/
ledipasvir,
elbasvir/grazoprevir,
SOF/VEL,
SOF/VEL/
voxilaprevir, glecaprevir/pibrentasvir, and ribavirin.
Data were systematically abstracted from clinical charts,
de-identified, and entered into an electronic database in a
standardized process. Three authors performed data extraction, database entry, and cross-checking. Statistical analyses
were performed using Excel, version 2016 (Microsoft). To ensure data accuracy, the expert clinician team member randomly
verified collected data. Discrepancies were addressed through
team discourse. Data were recoded as necessary.
Data Analysis

We descriptively examined patient baseline characteristics
using counts and percentages for categorical variables. The
continuous variable age was grouped into age range categories.
We evaluated differences in continuous variables using 2-tailed
t tests and assessed differences in binary categorical variables
using the pooled z-test statistic for differences in proportions. We applied the .05 alpha level for assessing statistical
significance.
The numerator for the intention-to-treat (ITT) SVR calculation was the number of patients with undetectable HCV VL
12 weeks post-EOT or at the first follow-up time point past this
scheduled SVR date. The denominator consisted of all patients
with an available SVR result (achieving or not achieving), excluded patients not yet due for SVR and patients still on treatment at the end of data collection, but included patients starting
treatment and lost to follow-up (LTFU) after initiating DAAs
and reaching SVR.
The modified ITT (mITT) SVR numerator was calculated as
the number of patients with undetectable HCV viral load 12
weeks post-EOT or at the first follow-up time point past this
scheduled SVR date. The denominator consisted of all patients
Colocated HCV/Opioid Agonist Therapy • ofid • 3
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medication lists, assists with drug–drug interactions, calls in
approved prescriptions, coordinates with numerous pharmacies to expedite DAA acquisition, ensure that refills are obtained
on time as DAAs are dispensed monthly, supports adherence,
and maintains the clinic database.
The second visit is treatment initiation, held once the payer
approves DAAs, typically within 3 weeks. For women of childbearing potential, urine pregnancy testing is performed to ensure a negative result. The first DAA dose is witnessed. Snacks
are supplied to patients who contend with food insecurity and
cannot eat before DAAs that require food. Individualized plans
are developed regarding when patients will take DAAs, storage,
refills, and HR. During treatment, patients may see the nurse
or doctor with questions 5 days per week. Given the substantial
prevalence of ongoing injection and polysubstance use, the staff
recommends that patients see the physician or nurse at week 2
for discussing adherence, liver panel to gauge biochemical response, and HCV RNA. Liver panel and HCV RNA are checked
at end of treatment (EOT) and post-treatment week 12, with additional laboratory monitoring and check-ins for patients with
medical risk. SVR visits focus on next health steps, prioritizing
tobacco cessation. Prompt retreatment is offered following reinfection. Reinfection visits afford opportunity to evaluate for
other infectious consequences of injection drug use (IDU),
PrEP, and OAT dose evaluation.

Table 1. Demographics and Clinical Characteristics of 275 HCV-Infected
Patients on OAT Treated for HCV
Characteristics
Age, y

Total Treated (n = 275)
No. (%)

21–30

46 (16.7)

31–40

91 (33.1)

41–50

53 (19.3)

51–60

54 (19.6)

61–70

30 (10.9)

71–80

1 (0.4)

Gender
F

95 (34.5)

M

180 (65.5)

HCV genotype
1a

158 (57.5)

1b

16 (5.8)

2

17 (6.2)

3

61 (22.2)

4

18 (6.5)

6

1 (0.4)

Mixed

4 (1.5)

Other liver disease
HIV/HCV
HBV/HCV
Cirrhosis
  Compensated
  Decompensated

4 (1.5)
4 (1.5)
64 (23.3)
57 (20.7)
7 (2.5)

RESULTS

Insurance

Baseline Characteristics of DAA-Treated Patients

  Medicaid

253 (92.0)

  Medicare

17 (6.2)

From May 1, 2014, to October 31, 2019, 426 patients underwent initial HCV physician evaluation. Of these, 275 (64.6%)
initiated DAAs, with a mean age (range) of 43 (22–71) years,
34.5% female, and 57.5% genotype 1a (Table 1). Sixty-four
(23.3%) had cirrhosis at presentation; of these, 7 (2.5%) presented with decompensated cirrhosis. Most patients, 92%,
were Medicaid recipients, under the following Medicaid plans:
53.1% Neighborhood Health, 26.9% United Health, 16.9% RI
Medicaid, 4.7% Tufts Health, 0.4% Mass Health.
One patient presenting with cirrhosis was diagnosed with HCC
shortly after initial HCV evaluation and achieved SVR and longterm remission. A second patient presenting with cirrhosis was
diagnosed with HCV-associated intrahepatic cholangiocarcinoma
shortly after achieving SVR and died from this malignancy. A third
presenting with cirrhosis was diagnosed with HCC 6 months postSVR. For this patient, Medicaid denied the prescription for an optimal regimen, approving only a shortened treatment course. The
patient did not achieve SVR with this first DAA regimen despite
reporting perfect adherence. He was then promptly prescribed
and Medicaid-approved for a second treatment course with an
extended regimen. He achieved SVR following retreatment, then
subsequently developed HCC and died.
SVR

Of the 275 patients who initiated DAAs, 2 were still awaiting
SVR at the end of data collection (Figure 2). Of the 273 patients
4 • ofid • Habchi et al

Public

Private

270 (98.2)

5 (1.8)

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; OAT, opioid agonist therapy.

who were 12 weeks or more post-EOT, 232 patients had an undetectable HCV VL 12 weeks post-EOT or at the first follow-up
time point past their scheduled SVR date. The ITT SVR was
85.0% (232/273). Twenty-four patients were LTFU, meaning
they were missing SVR results 12 weeks or more post-EOT.
Seventeen patients did not achieve SVR. The mITT SVR was
93.2% (232/249).
There was a difference in mean age between patients who did
and did not achieve SVR (difference, 6.6 years; 95% CI, 1.8 to
11.9; P < .01). Patients achieving SVR were older, with a mean
age (range) of 44 (22–71) years; for patients not achieving SVR,
the mean age (range) was 37 (23–55) years. No gender differences were found between patients who did and did not achieve
SVR (difference of proportions, 2%; 95% CI, –1.3% to 1.3%;
P = .4).
Reinfection

Of 275 patients initiating DAAs, 30 reinfections occurred
over 375.5 person years of follow-up, for a reinfection rate of
7.99 (95% CI, 5.1 to 10.8) per 100 person-years. The median
time to first reinfection was 128 days, with an IQR from 85.25
to 202.5 days. Sensitivity analyses conducted to determine

Downloaded from https://academic.oup.com/ofid/article/7/10/ofaa310/5921596 by guest on 30 October 2020

with available SVR results. The patients initiating treatment
and LTFU were excluded from the denominator, as were patients not yet due for SVR and patients still on treatment. In
the analysis of patients who did and did not achieve SVR, age
and gender differences were compared with a 2-tailed t test and
pooled z-test, respectively.
Reinfection rate was calculated as the number of reinfections
divided by the at-risk person time between EOT and end of data
collection for patients who were not reinfected, or the assumed
date of reinfection for reinfected patients, defined as the midpoint between EOT and the first follow-up date with detectable
HCV RNA [19, 20]. The following sensitivity analyses were carried out: At-risk person time was calculated as time between
SVR date and the first follow-up date with detectable HCV
RNA, and at-risk person time was calculated as time between
SVR date and the midpoint between the SVR date and the first
follow-up date with detectable HCV RNA [19, 20]. Median time
to the first reinfection and interquartile range (IQR) were calculated and reported in days. In the analysis of patients who
achieved SVR and were reinfected, comparisons of patients
who were and were not reinfected were conducted to assess age
and gender differences using a 2-tailed t test and pooled z-test,
respectively.

Patients initiated DAAs
N = 275 (100%)

Awaiting SVR
N=2

Lost to follow-up
N = 24/273 (8.8%)

ITT SVR
N = 232/273 (85.0%)

DAA treatment outcomes.

whether the reinfection rate would differ under alternate definitions of date of reinfection revealed nearly identical results
(not shown).
There was a difference in mean age between those who
were and were not reinfected (difference, 4.9 years; 95% CI,
–9.1 to –0.6; P < .01). Reinfected patients were younger, with
a mean age (range) of 39 (25–56) years; for patients not reinfected, the mean age (range) was 44 (22–71) years. No gender
differences were found between those who were and were not
reinfected.

Table 2.

Treatment and Medicaid Restrictions

Seventy-two patients initiated DAAs under Medicaid restrictions (November 1, 2014–June 30, 2018), with mean age of
55 (30–71 years), 26.4% female, and 69.4% having cirrhosis
(Table 2). From July 1, 2018, to October 31, 2019, 109 patients
initiated DAAs, with a mean age (range) of 39 (22–65) years,
38.5% female, and 9.2% having cirrhosis. This analysis excludes
94 patients treated through a study providing DAAs. There was
a difference in mean age between those initiating treatment before and after lifting restrictions (difference, 15.8 years; 95% CI,

Characteristics of Patients Initiating DAAs Before and After Lifting Medicaid DAA Restrictions
Initiated DAAs November 2014–June 2018

Initiated DAAs July 2018–October 2019

a

a

Age, y

n = 72, No. (%)

Difference of Means,b P

n = 109, No. (%)

21–30

1 (1.4)

26 (23.9)

31–40

7 (7.7)

42 (38.5)

41–50

14 (14.4)

20 (18.2)

51–60

26 (26.1)

17 (15.6)

61–70

23 (23.9)

4 (3.7)

71–80

1 (1.4)

<.001

–

Gender
F

19 (26.4)

44 (38.5)

M

53 (73.6)

67 (61.5)

Cirrhosis

50 (69.4)

10 (9.2)

44 (61.1)

9 (8.3)

6 (8.3)

1 (0.9)

  Compensated
  Decompensated

.064
<.001

Insurance
69 (95.8)

107 (98.2)

  Medicaid

Public

56 (77.8)

106 (97.2)

  Medicare

13 (18.1)

1 (0.9)

3 (4.2)

2 (1.8)

Private
Abbreviation: DAA, direct-acting antiviral agent.
a

Excludes 94 patients treated in a study using sofosbuvir/velpatasvir.

b

P values represent difference of means between the pre- and post-Medicaid restriction removal groups.
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Legend
DAAs = Direct-acting antivirals
SVR = Sustained virologic response
ITT = Intent-to-treat
mITT = Modified intent-to-treat

mITT SVR
N = 232/249 (93.2%)

Figure 2.

Treatment failure
N = 17/273 (6.2%)

12.6 to 19; P < .001). With restrictions, most treated patients
were >50 (67.3%), while once restrictions ended, a fifth (19.8%)
were >50. There was a difference in the proportion with cirrhosis between those initiating DAAs before and after removing
restrictions (difference, –59.3%; P < .001). With restrictions, 72
patients accessed DAAs over 3.7 years; without restrictions, 109
patients accessed DAAs over 1.3 years.
DISCUSSION

Leveraging OATP infrastructure for on-site HCV care

Medical care

HCV universaol “Test to Treat”

• Primary care
• Psychiatry

• Universal, opt-out HCV screening
• Accelerated, streamlined care
•Minimal blood work
• Serum biomarkers in place of elastography
• Education
• Post-treatment care

Prevention
• Harm reduction (NSP, naloxone)
• HIV PreP
• HAV & HBV vaccinations

• HIV
• HBV
• STIs
• Wound care
Services
• Counseling
• Peer support
• Housing/employment assistance
Frequent attendance

Supportive environment
for HCV treatment
• Staff familiar with psychosocial needs
• Low threshold care

Infectious disease care

• Daily/frequent contact
• DAA DOT
Legend

= Ideal care model extensions

NSP = Needle & syringe program
HIV = Human immunodeficiency virus
PreP = Pre-exposure prophylaxis

Figure 3.

Leveraging MMP infrastructure for on-site HCV care.
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HAV = Hepatitis A virus
HBV = Hepatitis B virus
HCV = Hepatitis C virus
DAA = Direct-acting antivirals
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Our findings show that people who initiated DAAs in an
urban MMP achieved high levels of SVR. This outcome in a
real-world setting demonstrates how effective HCV clinical
management can be for a marginalized US population on OAT
without access to ideal multidisciplinary care—without on-site
primary or psychiatric care, common among US MMPs. Our
approach incorporating colocated HCV and OAT treatment,
HR, flexible health care delivery, and universal “test to treat”
delivered in a resource-limited setting can inform models of
service delivery.
Our SVR rate (85%) is comparable to those from studies
of DAAs in similar populations. A systematic review and
meta-analysis of international DAA treatment outcomes reports SVR of 87.4% among people with recent IDU and 90.7%
among those receiving OAT [2]. An even more recent prospective, open-label, observational trial at an HR organization in
Washington DC reports SVR of 82% among 100 patients with
OUD and ongoing IDU treated with SOF/VEL and offered concurrent buprenorphine initiation [21]. Two US retrospective
evaluations of real-world colocated care reported SVR rates of

85% among 300 homeless-experienced individuals in Boston,
Massachusetts, treated at a Federally Qualified Health Center
providing integrated primary care and among 75 patients
treated at a New Haven, Connecticut, not-for-profit addiction
treatment program providing OAT with on-site primary and
psychiatric care [19, 22].
Another success of this “real-world” cohort was the low proportion loss to follow-up and patients evaluable for SVR (8.8%
of the ITT population). Engagement following DAA therapy is
necessary for determining SVR, managing cirrhosis, ongoing
HR, routine testing for reinfection, and prompt retreatment
[23]. Colocated OAT can improve retention in HCV care [22].
This may signify the HCV team’s experience in OUD, may reflect patients’ possible lack of a medical home, and/or may be
a consequence of patients being pharmacologically wedded
to OAT.
The SVR rate and low proportion lost to follow-up in the
absence of robust colocated ambulatory services could also
reflect the support and organization built into other aspects
of MMP care. MMPs are tightly structured, complex environments [15]. Following a physician assessment, patients ingest
a daily methadone dose under direct nursing observation.
Results of toxicology screens and compliance with behavioral
parameters dictate the number of carry-home doses, which
reduce the frequency of clinic attendance. This infrastructure may be leveraged for HCV care, which is important given
the high HCV prevalence at MMPs and failure of off-site referral (Figure 3) [24]. Comfortable, compassionate care can
be provided by staff cognizant of and working to ameliorate

and follow-up coordination and ultimately help expand treatment capacity.
The Veterans Administration (VA) is the largest provider of
HCV care in the United States. Their successful elimination
strategy includes pharmacist-led HCV management, an approach utilized globally. By 2017, one-fourth of VA DAA prescriptions were initiated by a network of 200 pharmacists [28].
Enabling community pharmacists—highly educated, underutilized health care workers—to prescribe DAAs with physician
collaboration for patients with advanced liver disease is another
key strategy to expand US treatment capacity.
This study has several limitations. It is from a single institution, retrospective, and limited to data collected within the
context of routine clinical care. We lack a viral hepatitis surveillance system. We do not have data on the total number of
patients screened and diagnosed with HCV. We only had staff
to enter detailed data for patients prescribed DAAs. While delays in obtaining SVR testing were common, we did not record
the date of actual SVR. We do not have data on the untreated
population, nor on patient-level factors possibly associated
with lack of SVR or reinfection, such as ongoing substance use
and polysubstance use, mean OAT dose, or housing status. To
strengthen respect and trust, we do not collect data on ongoing
substance use, nor do we access the methadone clinic electronic
health record (EHR), which contains this information. We work
to develop system-level enhancements to overcome individual
baseline characteristics. Most patients receive methadone maintenance, with a small minority prescribed buprenorphine/naloxone (Medicaid patients could not access buprenorphine until
2016); we do not have data on the exact percentage.
CONCLUSIONS

DAA treatment is effective among patients with OUD receiving
colocated HCV care in a US resource-limited inner-city MMP.
“One-stop shopping” with simplified pretreatment assessment
and serum biomarkers to stage fibrosis accelerates the path to
cure. Eliminating the PA process and remaining state DAA restrictions will expedite treatment initiation following diagnosis
to reduce viremic time and incidence.
How can we incorporate HCV management into over 1600
US MMPs [29]? Financial challenges are a limiting factor. US
health insurance and payment systems poorly reimburse HCV
outpatient care. Models that improve the business case for HCV
management without income from procedural billing for endoscopy, colonoscopy and radiology are needed to achieve financial sustainability at MMPs. Extending state and federal
support for OUD to support HCV care would help. Virtual
colocation via telemedicine can aid in HCV treatment rollout.
Telemedicine imports HCV management into locales convenient for and familiar to patients, but lacking HCV expertise, infrastructure, and resources [30].
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the hardships faced by clients contending with OUD. Nursing
services, peer support, mental health care and housing assistance may be offered. Regular contact presents opportunity
for everyday support and time for development of therapeutic
relationships.
Conversely, there are problems with MMPs. Methadone is
the most common form of OAT in the United States [25]. The
US federal 1974 Narcotic Addict Treatment Act mandated that
patients attend a federally licensed clinic for methadone maintenance [15]. This created an MMP system outside of mainstream health care, in which medical standards of care are not
always fully incorporated, care beyond dispensing methadone
may be limited, and patients are ghettoized with patients with
the same diagnosis [15].
The reinfection rate observed in this study is similar to that
of other cohorts of PWID on OAT in the DAA era with ongoing IDU. Data are limited on reinfection rates among patients
on OAT post-DAA therapy in the United States. Among a New
York cohort of PWID on OAT, incidence of reinfection was 7.4
per 100 person-years among those reporting ongoing IDU [6].
In a recent meta-analysis, the reinfection rate was 5.9 per 100
person-years among PWID receiving OAT with recent drug
use [26]. Near Rhode Island, among a homeless population in
Boston, Massachusetts, the reinfection rate was 13.1 per 100
person-years [19].
CODAC Providence is situated in a hotspot of drug activity and overdose. NSP is available nearby but not on-site.
Mounting fentanyl and methamphetamine use may contribute to more frequent injecting behavior. While OAT
curtails opioid use, it does not hinder use of stimulants,
benzodiazepines, or alcohol, and its efficacy can be compromised by use of these substances. An insufficient number
of RI providers prescribing DAAs to drug-involved populations and slow scale-up of HCV treatment may also contribute to reinfection.
The timing of this evaluation highlights the impact of removing DAA restrictions. At program inception, we prioritized
older patients, those at risk for advanced fibrosis, and those who
were better able to access DAAs under fibrosis restrictions [27].
We were unable to treat HCV before progression to advanced
fibrosis—typically in younger patients, often the transmitting
population. The remaining US DAA restrictions should be
abolished.
Adding a pharmacist to our team, along with ending DAA
restrictions, supported treating more people in the year after
restrictions ended than in the 4 years prior. The time- and labor-intensive PA processes remain a modifiable barrier to
expanding treatment capacity as we aim for test to treat with
same-day DAA initiation. It is time to eliminate the DAA
PA process. Without the PA process, or with a simplified PA
process, the pharmacist could undertake more clinical responsibilities such as treatment initiation visits, adherence support,

Determining the essential components of colocated OAT/
HCV care to optimize outcomes requires additional study. To
mitigate the syndemic of HCV and addiction, alternative payment and financing sources must be identified. Methadone
must become more accessible across a range of clinical settings
including primary care and community pharmacies, while the
full spectrum of HCV services should be offered on-site at OAT
programs via a holistic, patient-centered approach that best
meets the needs of drug-involved populations.
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